STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial

Inclusion Criteria: * Age ≥18 years * De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm * Single- or multi-vessel disease with only 1 lesion meeting the definition of severe stenosis and anatomically amenable to coronary revascularization using DCB alone judged by physician. * Severe stenosis is defined if 1 of the following criteria are met: 1. visual angiographic stenosis with severity \>= 70%. 2. functional stenosis with quantitative flow reserve (QFR) or fractional flow reserve (FFR) \< 0.8. * The prospective subject is agreed on participating the study with a formal written consent Exclusion Criteria: * Acute myocardial infarction\* (STEMI or NSTEMI) within the past one month * Diagnosis of myocardial infarction (MI) requires both clinical evidence of myocardial ischemia and elevation of cardiac Troponin (cTn) I or T values with at least 1 value above the 99th percentile upper normal range limit (URL) * Clinical evidence of myocardial ischemia is defined as 1 of the following: 1. Symptoms of myocardial ischemia 2. New ischemic ECG changes 3. Development of pathological Q waves 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology 5. Identification of a coronary thrombus by angiography * Type 1 MI defined by "the Fourth Universal Definition of Myocardial Infarction (2018)", which occurred within the last one month from inclusion phase would be excluded from this study. * Patients who have received percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) within 12 months on the target vessel before the index procedure. * Currently recommended indications for DCB: in-stent restenosis, complex bifurcation lesions requiring concomitant intervention of the major vessel and its adjacent side branch (e.g., lesions requiring dual stent implantation, kissing balloon technique, etc.) * Lesions with any of the following anatomical characteristics presumably not suitable for DCB treatment: 1. long lesion with length \>= 40mm. 2. severe tortuous, or severe angulated vessels, especially when vessel recoil seems possible. 3. Chronic total occlusion * Definition: A lesion of a coronary artery becomes completely blocked for a duration of greater than or equal to 3 months based on angiographic evidence. 4. lesions in left main coronary artery 5. lesions in venous or arterial graft * Chronic heart failure with left ventricular ejection fraction \< 35% after 6 months of Guideline-Directed Medical Treatment (GDMT) * Acute heart failure, hemodynamic instability, or cardiogenic shock * Acute heart failure is defined as a rapid onset of new or worsening signs and symptoms of heart failure. * Non-cardiac Comorbidities: 1. Severe liver insufficiency defined as 1 of the following: * alanine transaminase or aspartate transaminase more than 5-fold of upper reference limit. * Child-Pugh grade B or C. 2. Severe renal insufficiency with estimated glomerular filtration rate \< 30 ml/min/1.73m2. 3. Malignant tumor. 4. A life expectancy of less than 1 year. * Unsuitable for coronary intervention or long-term antithrombotic therapy 1. Myocardial bridging located at target lesions. 2. Major bleeding (BARC type 3 to 5) or active pathological bleeding (including gastrointestinal or genitourinary bleeding) within 3 months, or major surgery within 2 months. 3. Intolerable to double (aspirin plus P2Y12 inhibitor) or single (aspirin or P2Y12 inhibitor) antiplatelet therapy. 4. History of intracranial hemorrhage. 5. Pregnant women, lactating women, and women of childbearing potential. * History of artificial valve replacement. * History of participating in any other clinical studies or trials within 12 months before the index procedure. * Participants deemed unsuitable to be enrolled by investigators, such as conditions that may result in protocol nonadherence.